Business
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the
About this update from Exelixis, Inc.
[{"type":"text","content":"\n- Presentations to be webcast on www.exelixis.com -\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nExelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November and December of 2021:\n\n\nBMO Biopharma Spotlight Series: Oncology: Exelixis is scheduled to present at 12:10 p.m. ET / 9:10 a.m. PT on Monday, November 8.\n\n\nCredit Suisse 30th Annual Virtual Healthcare Conference: Exelixis is scheduled to present at 1:50 p.m. ET / 10:50 a.m. PT on Wednesday, November 10.\n\n\nStifel 2021 Healthcare Conference: Exelixis is scheduled to present at 4:40 p.m. ET / 1:40 p.m. PT on Tuesday, November 16.\n\n\nPiper Sandler 33rd Annual Virtual Healthcare Conference: Exelixis’ presentation session will be available to view on-demand beginning 10:00 a.m. ET / 7:00 a.m. PT on Monday, November 22.\n\n\nEvercore ISI 4th Annual HealthConX Virtual Conference: Exelixis is scheduled to present at 11:45am ET / 8:45am PT on Wednesday, December 1.\n\n\nTo access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.\n\nAbout Exelixis\n\nFounded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting i...